Medical technology company Teleflex (NYSE:TFX) missed Wall Street’s revenue expectations in Q4 CY2025, with sales falling 28.5% year on year to $569 million. Its non-GAAP profit of $1.93 per share was ...

Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

Over the last six months, Teleflex’s shares have sunk to $113.26, producing a disappointing 13% loss - a stark contrast to ...

Tejara Capital Ltd disclosed a buy of 69,700 Teleflex (NYSE:TFX) shares in a February 5 SEC filing, with an estimated transaction value of $8.45 million based on quarterly average pricing. According ...

Teleflex’s TFX broad Vascular Access portfolio is poised to continue to win shares through its category leadership in Central Venous Catheters (CVC), midlines and new launches. The company’s expansion ...

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...

Teleflex (TFX) delivered earnings and revenue surprises of -48.27% and -38.55%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Teleflex Inc. TFX slid 1.09% to $107.81 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.36% to 6,624.70 and ...